One company that has started to make a name for its self in the medical and financial community is ImmunoCellular Therapeutics. Located in Los Angeles, California, ImmunoCellular is a clinical stage company that is developing immune-based therapies for the treatment of brain and other cancers. Today, the young company took a major step towards enhancing its future with the announcement they have received a notice of allowance for a new patent for its antibody ICT-69.
The ICT-69 is a revolutionary antibody because it targets multiple myeloma and ovarian cancers. The ICT-69 has been successful in that it has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
This news will allow ImmunoCellular to continue its already strong appeal to consumers and perhaps more importantly, cancer patients. With 7 granted US patents and 8 issued international patents, this new patent will enable a broad extension of intellectual property to cover other chimeric antibodies or antibody-conjugates targeting the same antigen.
One of the ways ImmunoCellular has helped the ICT-69 evolve is through a research and option agreement with the Roche Group who is a renowned name in the field of diagnostics and pharmaceuticals. The Roche Group and ImmunoCellular make for a strong combination in their industry and may lead to significant advancements in the treatment of cancer.
Under the terms of the agreement, ImmunoCellular will allow Roche the rights to investigate the potential of ICT-69 for an upfront payment. Should the antibody be successful in the treatment of ovarian cancer and multiple myeloma and reach the agreed upon developmental milestones, Roche would have payments due to ImmunoCellular to the total of $32 million.
Leading the way at ImmunoCellular is Manish Singh, PhD who serves as the company President and CEO. When asked about the future of ImmunoCellular, Dr. Singh was quoted as saying, “This approval strengthens our intellectual property rights and potential value of our product ICT-69 significantly. We continue to be excited about working with the Roche Group in the development of this product.”
With the potential for the ICT-69 and a deal with a leading company such as the Roche Group in place, ImmunoCellular is quickly becoming a recognized company on Wall Street.
Currently, ImmunoCellular Therapeutics is trading in the $0.85 range. With an array of patents in their pipeline and their continual improvement in medical technology and the treatment of cancer, ImmunoCellular is a company on the rise. To learn more about ImmunoCellular, visit their website at: www.imuc.com.
Let’s hear your thoughts below: